Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for blood clues to make nut allergy treatment safer

NCT ID NCT06554691

Knowledge-focused Sponsor: Luxembourg Institute of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines blood samples from 90 children with peanut or tree nut allergies to find immune markers that show how well oral immunotherapy is working. Researchers compare kids receiving immunotherapy, those avoiding nuts, and healthy adults. The goal is to develop better ways to monitor treatment and personalize care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For peanut and tree nut-allergic cohort, participants are selected from the Immnulogy and Allergology Deparment at the Centre Hospitalier de Luxembourg. For the healthy adults cohort, participants are recruited from the Luxembourg population.

Ages

2 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For Peanut and Tree nut Allergic participants Inclusion criteria: * More than 2 years * Male or Female * Allergic to peanut (assessed by anamnesis, skin reactivity testing, sera testing for specific IgE) * Sign an Informed Consent Exclusion criteria: * Pregnancy * Less than 2 years of age * Co-existing chronic medical condition such as cardiovascular disorders * Peanut or tree nut-allergic patients/families who are unwilling to undergo oral food challenges The eligible participants will be assigned to the oral immunotherapy (OIT) group but if they are not eligible for OIT based on either on the reasons mentioned below, they will be assigned to the avoidance group. Reasons for ineligibility of OIT : * risk of poor compliance with immunotherapy * lack of understanding of the OIT protocol * uncontrolled asthma * incompatibility with lifestyle (regular intense physical activities, multiple vacations) * unwilling to undergo OIT * long-term or frequent use of non-steroidal anti-inflammatory drugs * multiple nut allergy with no direct clinical benefit of OIT to one nut * co-existing comorbidities such as active systemic autoimmune diseases, active malignancy, eosinophilic esophagitis. For Healthy Controls Inclusion Criteria: * Adults * Male or Female * Sign an Informed Consent * Tolerates any type of nut * No known food allergy Exclusion Criteria: * Pregnancy * Co-existing chronic medical condition such as cardiovascular disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy;food are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

food allergy Nut Hypersensitivity Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy;food Food allergy Food allergy in children Food allergy peanut Oral immunotherapy for food allergy Tree nut allergies

Contacts and locations

Locations

  • Centre Hospitalier de Luxembourg

    Luxembourg, 1210, Luxembourg

  • Clinical and Epidemiological Investigation Center, Luxembourg Institute of Health

    Luxembourg, 1210, Luxembourg

More trials for these conditions

Other studies related to the condition(s) this trial covers.